Growth Hormone Research Market

GHRP-6

A classic growth hormone secretagogue that remains common in peptide-market catalogs despite limited mainstream clinical relevance.

Growth HormoneSecretagogueResearch Market

Also appears in: Muscle Growth

Price compare
10 tracked offers across 10 vendors · 5 dosages
Best trust-adjusted value: Kimera Chems · Strong trust · $4.40/mg
From
$2.73/mg
Status
Research Market

This name primarily lives in the research market and should not be read like an approved pharmaceutical product.

Category
Growth Hormone

Primary lane: Growth Hormone. Also surfaces under Muscle Growth for browsing and discovery.

Aliases
0

No major aliases are tracked for this profile yet.

Signal depth
Low

No FDA label signal · 0 trials · 634 PubMed results

Preclinical
Research evidence

Current evidence for GHRP-6 is limited to laboratory or animal studies — there are no name-matched human trials with reported results. Any claims about effects in people are not yet backed by clinical data.

GHRP-6 has no clinical trials that name it and 634 PubMed-indexed publications and is not FDA-approved. Current evidence is preclinical or mechanistic.

Human data
Lab / animal only
Trial quality
No human trials
Outcomes
No human trials
Replication
Multiple papers
Literature
High-impact
The Journal of Clinical Endocrinology & Metabolism · 190 citations Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary disconnection: evidence that GHRP-6 main action is exerted at the hypothalamic level. The Journal of Clinical Endocrinology & Metabolism · 147 citations Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesity. European Journal of Pharmacology · 142 citations Comparison of the gastroprokinetic effects of ghrelin, GHRP-6 and motilin in rats in vivo and in vitro Journal Article The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Journal Article The Ghrelin/GHSR-1a Axis Attenuates Preeclampsia-like Features with Decidual Macrophage Reprogramming and Improved Placental Remodeling. Journal Article Growth Hormone-Releasing Peptide-6 (GHRP-6) Ameliorates Post-Infarct Ventricular Remodeling and Systolic Dysfunction in a Model of Permanent Coronary Ligation.
Evidence history

Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-07-13 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What GHRP-6 is

GHRP-6 is a growth hormone secretagogue that has long circulated in bodybuilding and research-market communities. It is one of the foundational names in the GH peptide niche.

Why it matters

Even if newer categories attract more attention today, GHRP-6 helps explain the older structure of the peptide market and why GH-oriented compounds still occupy a separate lane.

Regulatory context

GHRP-6 is not FDA approved in the United States for performance or GH optimization use.

Practical reading note

This is a category where historical community use often gets mistaken for modern clinical legitimacy, and the two are not the same thing.